CFB
RARE icon

Cullen/Frost Bankers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cullen/Frost Bankers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36
Closed -$1.48K – 1348
2024
Q2 		$1.48K Buy
+36
New +$1.54K ﹤0.01% 1151

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cullen/Frost Bankers's RARE Position: Q3 2024 in Review

Cullen/Frost Bankers sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 36 shares — an estimated $1.48K sold.

Cullen/Frost Bankers first reported a position in RARE in Q2 2024 and held it in 1 quarter. The position peaked at $1.48K in Q2 2024. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Cullen/Frost Bankers reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Cullen/Frost Bankers sold 36 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $1.48K.
  • Cullen/Frost Bankers first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 1 quarter.
  • Cullen/Frost Bankers's Ultragenyx Pharmaceutical position peaked at $1.48K in Q2 2024.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Cullen/Frost Bankers's 13F filing for Q3 2024, filed 6 Nov 2024.